This paper compares the reimbursements 340B hospitals receive from commercial insurers for brand physician-administered medicines to the estimated prices these hospitals pay to acquire the medicines. It also evaluates how differences between estimated acquisition costs and reimbursements for 340B hospitals compare to non-304B hospitals.

This report was commissioned by Pharmaceutical Research and Manufacturers of America.